• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Press release July 7, 2021

SRI International enters drug discovery and research collaboration with Sanofi

MENLO PARK, Calif., July 7, 2021 – SRI International (SRI) today announced that the company has entered a research collaboration with Sanofi. By leveraging SRI’s SynFini™ platform, an artificial intelligence (AI)-guided, automated synthetic-chemistry system, the collaboration will discover and develop lead candidates in multiple high-profile drug-discovery programs at Sanofi.

SRI’s SynFini platform combines AI and automation to accelerate small molecule drug discovery and development, and thereby bring new drugs to the clinic more quickly and affordably. The platform comprises three components (SynRoute™, SynJet™ and AutoSyn™) that work seamlessly together to automate synthetic route design, reaction screening and optimization (RSO), and production of target molecules.

“The goal of the SynFini platform is to create a new paradigm in the approach to drug discovery,” said Nathan Collins, chief strategy officer of SRI’s Biosciences Division and head of the SynFini program. “We look forward to working with Sanofi in applying our AI-guided automation platform to drive the rapid and efficient discovery of therapeutics for high-profile targets.”

The SRI-Sanofi collaboration will also use SRI’s recently implemented DASLTM (Deep Adaptive Semantic Logic) AI-guided molecular design tool for multi-parametric optimization in hit-to-lead and lead optimization. Utilizing reasoning-guided deep neural networks, DASL efficiently predicts drug designs from the sparse data sets that are typically available in drug discovery.

About SRI International
SRI International creates world-changing solutions making people safer, healthier and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education. SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new product solutions.

#  #  #

Media Contact:
Michele Parisi
For SRI International
mparisi@forwardhealthinc.com
1-925-864-5028

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International